Login to Your Account



$53M Added To Chromatin For CHR-2797 Phase II Trial

By Nuala Moran


Wednesday, April 5, 2006
LONDON - Chromatin biology specialist Chroma Therapeutics raised £53 million in a third-round funding, enabling it to move the lead program CHR-2797 through Phase II studies and get two other compounds into the clinic. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription